Novel Injection Dose and Delivery of Varicella-Zoster Virus Vaccine
The immunogenicity of low dose VZV vaccine delivered into the outer layers of skin compared with the standard dose delivered conventionally is investigated.
The immunogenicity of low dose VZV vaccine delivered into the outer layers of skin compared with the standard dose delivered conventionally is investigated.
For adults aged 50 years or older, those with a COVID-19 diagnosis have an increased risk for developing herpes zoster.
Recommendations have been updated for use of the recombinant zoster vaccine (RZV) for prevention of herpes zoster and related complications among immunocompromised adults aged 19 years and older.
Researchers evaluated the management of herpes zoster in patients with rheumatoid arthritis and psoriatic arthritis receiving tofacitinib treatment.
Investigators conducted a study to estimate global herpes zoster virus incidence rates in the general population.
Do you advise your patients to get the HZ vaccine after their initial outbreak of shingles?
Previously, the vaccine was only approved for adults 50 years of age and older.
Investigators sought to assess the impact of age and vaccination status on rates of herpes zoster in a pediatric population.
Researchers support additional antiviral treatment following penetrating keratoplasty.
Investigators conducted an observational, retrospective study to assess variables associated with poor outcomes in patients with varicella-zoster virus infection with central nervous system involvement.